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Clear cell differentiation may be occasionally seen in various sub-
types of breast cancer, but pure forms of clear cell carcinoma (>90% 
clear cell morphology) are exceptionally rare. These cancers are char-
acterized by neoplastic cells with an abundant and clear cytoplasm 
that typically contains glycogen.1 This type of cancer is considered 
a distinct cyto-morphological pattern of invasive breast carcinoma 
of no special type (IBC-NST).1 The clinical data on clear cell carci-
noma are limited and predominantly include small retrospective 
studies that reported the conflicting results.2 However, a recent 
Surveillance, Epidemiology, and End Results (SEER) study revealed 
that clear cell carcinomas tend to be pathologically high-grade can-
cers that clinically present at an advanced stage and have poor out-
comes.3 Apart from reports of variable steroid receptor (ER and PR) 
and HER2 positivity, no studies have systematically explored molec-
ular features and potentially targetable biomarkers in clear cell car-
cinomas.2 Herein, we profiled nine pure clear cell carcinomas of the 
breast using massively parallel DNA and RNA sequencing (NGS), in 
situ hybridization (ISH), and immunohistochemistry (IHC). All cases 
were primary mammary clear cell carcinomas that were diagnosed in 
female patients (mean age: 53.4 years; range: 31-69 years) (Figure 1). 
Six out of nine cases were periodic acid-Schiff (PAS) positive and 
PAS-diastase sensitive (glycogen-rich). The NGS platform covered 
exons from 592 genes (SureSelect XT, Agilent, Santa Clara, CA; and 
the NextSeq instrument, Illumina, San Diego, CA). The tumor mu-
tational burden (TMB) was considered high if ≥11 mutations/mega-
base were detected4 (Table 1). Microsatellite instability (MSI) was 
calculated from NGS data by direct analysis of short tandem repeat 
tracts in the target regions of sequenced genes.5 The ArcherDX 
FusionPlex Assay (ArcherDX, Boulder, CO) was used for gene fu-
sion assessment (n = 54; Table 1). The following biomarkers were 
tested by immunohistochemistry (IHC): steroid receptors (ER, PR, 
AR, ARv7), HER2, pTRK, PD-L1, PTEN, and mismatch repair proteins 
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Abstract
We profiled nine pure clear cell carcinomas of the breast using massively parallel 
DNA and RNA sequencing (NGS), in situ hybridization (ISH), and immunohistochem-
istry (IHC). All cases were primary mammary clear cell carcinomas that were diag-
nosed in female patients (mean age: 53.4 years; range: 31-69 years). Based on our 
findings, we conclude that the majority of clear cell carcinomas are ER/PR positive 
and consequently amenable to anti-ER treatment modalities. A subset of clear cell 
carcinomas also harbored alterations in PIK3CA/PTEN/AKT pathway, particularly 
PTEN, indicating a potential benefit of PI3K/Akt/mTOR inhibitors. The status of I-O 
biomarkers in clear cell carcinomas indicates a limited therapeutic benefit of immune 
checkpoint inhibitors (against PD-1/PD-L1).
K E Y W O R D S
breast cancer, clear cell carcinoma, immunotherapy, molecular profiling, targeted therapy
2  |     SKENDERI Et al.
(MLH1, MSH2, MSH6, and PMS2) (clones and thresholds for posi-
tivity are provided in Table S1).4,6,7 Both ER and PR were positive in 
the majority of cases (8+/9 cases each) (Table 1). AR was positive in 
7/9 cases (78%) without the presence of the ARv7 splice variant. No 
case was HER2 positive by IHC or ISH (0%). Pathogenic mutations 
were detected in three cases: PIK3R1 and BRCA2 (#1); TP53, PTEN, 
and CDKN2A (#2); and TP53 and BCOR1 genes (#3) (Table 1). PTEN 
protein loss was confirmed by IHC in the one PTEN-mutated case as 
well as in two additional cases without detectable PTEN gene muta-
tions (Table 1). No gene fusion was detected in any of the cases. Low 
PD-L1 expression (1%-10%) was exclusively seen in immune cells in 
3/8 cases (Figure 1); notably, one of the PD-L1 + cases had an under-
lying PTEN gene mutation (Table 2, Figure 1). All tested cases (n = 8) 
were MSI stable (by NGS or IHC) and had low TMB (3-7 mutations/
megabase) (n = 4) (Table 2).
Based on our findings, we conclude that the majority of clear 
cell carcinomas are ER/PR positive and consequently amenable to 
anti-ER treatment modalities. Although not routinely assessed, the 
importance of AR expression in breast cancer has been increasingly 
recognized,1 particularly in triple-negative breast cancer (TNBC). 
Although we found frequent AR overexpression in clear cell carci-
nomas without the ARv7 splice variant, potential therapeutic benefit 
of anti-AR–based therapy alone in clear cell carcinomas expressing 
ER is uncertain. Alterations within the PI3K/Akt/mTOR pathway 
are among the most common genomic alterations in breast cancer.8 
A subset of clear cell carcinomas also harbored alterations in this 
pathway, particularly PTEN, indicating a potential benefit of PI3K/
Akt/mTOR inhibitors. A complete loss of PTEN protein expression 
without detected PTEN gene mutations in two cases indicates an al-
ternative silencing mechanism of this important tumor suppressor. 
The observed alterations in clear cell carcinomas may be clinically 
relevant given that the Food and Drug Administration (FDA) has re-
cently approved a PIK3CA inhibitor Piqray (alpelisib) combined with 
fulvestrant for the treatment of ER+/PIK3CA-mutated metastatic 
breast carcinomas. In addition, two of three clear cell carcinomas 
with PI3K/PTEN alterations were AR+. A recent clinical trial showed 
the therapeutic benefit of combined anti-AR (enzalutamide) and 
PIK3CA inhibitor (taselisib) in TNBC patients whose cancers were 
AR+.9 Interestingly, one of the clear cell cases harbored a CDKN2A 
(P16INK4A) gene mutation; several studies have revealed mutations 
in this gene in a proportion of breast carcinomas [reviewed in10]. 
The discovery of genetic alterations of CDKN2A as well as other cell 
cycle regulators in breast cancers has led to the approval of CDK4/6 
inhibitors (palbociclib) for the treatment of ER+/HER2- advanced/
metastatic breast carcinomas.10,11 In recent years, immunother-
apy based on immune checkpoint inhibitors (against PD-1/PD-L1) 
F I G U R E  1   Case #4: a tumor with clear 
cell morphology (left image, 20x) with PD-
L1 expression (~10%) detected exclusively 
in immune cells (right image) (PD-L1, 
SP142 clone, Ventana, 20x)
TA B L E  1   Overview of the potentially targetable biomarkers in cell carcinomas of the breast
Case ER and PR AR and ARv7 HER2 status Mutational profile
Gene fusions 
(NTRK)b 
#1 ER (+), PR (+) AR (+) Negative None None
#2 ER (+), PR (+) AR (−) Negative n/a None
#3 ER (+), PR (−) AR (+), ARv7 (−) Negative None None
#4 ER (+), PR (+) AR (+), ARv7 (−) Negative BRCA2, PIK3R1, PTEN lossa  None
#5 ER (+), PR (+) AR (+), ARv7 (−) Negative n/a None
#6 ER (+), PR (+) AR (+), ARv7 (−) Negative PTEN, TP53, CDKN2A None
#7 ER (+), PR (+) AR (+), ARv7 (−) Negative n/a None
#8 ER (+), PR (+) AR (+), ARv7 (−) Negative n/a None
#9 ER (−), PR (+) AR (−) Negative TP53, BCOR, PTEN lossa  None
Abbreviations: AR, androgen receptor; ARv7, androgen receptor splice variant 7; ER, estrogen receptor; HER2, human epidermal growth factor 
receptor 2; NTRK, neurotrophic receptor tyrosine kinase; PR, progesterone receptor.
aPTEN loss was observed by immunohistochemistry. Case #6 with PTEN gene mutation also exhibited PTEN protein loss by IHC. 
bArcherDX FusionPlex Assay (ArcherDX, Boulder, CO) was used to assess gene fusions (n = 54) (the panel is available here: https://www.caris molec 
ulari ntell igence.com/wp-conte nt/uploa ds/2017/03/TN027 6-v14_Profi le-Menu.pdf). NTRK status was also assessed by immunohistochemistry.¸  
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has dramatically improved the treatment options and outcomes of 
several cancers including TNBC. The selection of patients for these 
drugs is based on several predictive biomarkers (I-O biomarkers) in-
cluding PD-L1 expression (on cancer or immune cells) and TMB and 
MSI status. The status of I-O biomarkers in clear cell carcinomas indi-
cates a limited therapeutic benefit of immune checkpoint inhibitors 
(against PD-1/PD-L1). The presence of a PTEN mutation in one of the 
PD-L1+ cases may suggest resistance to immune checkpoint inhib-
itors.12,13 Nevertheless, finding immune cell PD-L1 expression in a 
subset of clear cell carcinomas warrants further investigations given 
the approved treatment for TNBC with atezolizumab is solely based 
on immune cell expression of PD-L1 (source: FDA, https://www.fda.
gov/drugs /drug-appro vals-and-datab ases/fda-appro ves-atezo lizum 
ab-pd-l1-posit ive-unres ectab le-local ly-advan ced-or-metas tatic -tripl 
e-negative, accessed on March 2, 2020). MSI and TMB status in clear 
cell carcinomas of the breast is similar to that in IBC-NST.14,15
In conclusion, clear cell carcinomas of the breast have limited 
targeted therapy options, but comprehensive molecular profiling 
may guide single or combined targeted treatments in selected 
cases.
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TA B L E  2   The status of immuno-oncology (I-O) biomarkers in 
clear cell carcinomas of the breast
I-O biomarkers Status in clear cell carcinomas
PD-L1 expression (n = 8) 3/8 positive in immune cells (1%-
10% positivity) No expression in 
cancer cells
Tumor mutational burden 
(TMB)a  (n = 4)
4/4 low (5-7 mutations/
megabase)




aTMB was considered high if ≥11 mutations/megabase were detected. 
The estimated threshold was based on a cohort of 603 triple-negative 
breast carcinomas of no special type using an 80th percentile cutoff 
value.14 
